VFA
SPRO icon

Valeo Financial Advisors’s Spero Therapeutics SPRO Stock Holding History

Valeo Financial Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$2K – 1702
2018
Q3 		$2K Hold
200
– – ﹤0.01% 1512
2018
Q2 		$2K Buy
+200
New +$2.56K ﹤0.01% 1379

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valeo Financial Advisors's SPRO Position: Q4 2018 in Review

Valeo Financial Advisors sold out of Spero Therapeutics (SPRO) in Q4 2018, closing a stake of 200 shares — an estimated $2K sold.

Valeo Financial Advisors first reported a position in SPRO in Q2 2018 and held it in 2 quarters. The position peaked at $2K in Q3 2018. 52 funds tracked by Wall St. Rank hold SPRO as of Q4 2018.

  • Valeo Financial Advisors reported no remaining Spero Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Valeo Financial Advisors sold 200 Spero Therapeutics shares in Q4 2018, an estimated $2K.
  • Valeo Financial Advisors first reported a position in Spero Therapeutics in Q2 2018 and held it in 2 quarters.
  • Valeo Financial Advisors's Spero Therapeutics position peaked at $2K in Q3 2018.
  • 52 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2018.

Based on Valeo Financial Advisors's 13F filing for Q4 2018, filed 30 Jan 2019.